Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL.
Diepstraten ST, et al. Among authors: strasser a.
Cancer Cell. 2024 May 13;42(5):850-868.e9. doi: 10.1016/j.ccell.2024.04.004. Epub 2024 Apr 25.
Cancer Cell. 2024.
PMID: 38670091
Free article.